BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34779407)

  • 1. LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy.
    Missios P; da Rocha EL; Pearson DS; Philipp J; Aleman MM; Pirouz M; Farache D; Franses JW; Kubaczka C; Tsanov KM; Jha DK; Pepe-Mooney B; Powers JT; Gregory RI; Lee AS; Dominguez D; Ting DT; Daley GQ
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.
    Beckers A; Van Peer G; Carter DR; Gartlgruber M; Herrmann C; Agarwal S; Helsmoortel HH; Althoff K; Molenaar JJ; Cheung BB; Schulte JH; Benoit Y; Shohet JM; Westermann F; Marshall GM; Vandesompele J; De Preter K; Speleman F
    Cancer Lett; 2015 Sep; 366(1):123-32. PubMed ID: 26123663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors.
    Tao T; Shi H; Mariani L; Abraham BJ; Durbin AD; Zimmerman MW; Powers JT; Missios P; Ross KN; Perez-Atayde AR; Bulyk ML; Young RA; Daley GQ; Look AT
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16516-16526. PubMed ID: 32601179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.
    Molenaar JJ; Domingo-Fernández R; Ebus ME; Lindner S; Koster J; Drabek K; Mestdagh P; van Sluis P; Valentijn LJ; van Nes J; Broekmans M; Haneveld F; Volckmann R; Bray I; Heukamp L; Sprüssel A; Thor T; Kieckbusch K; Klein-Hitpass L; Fischer M; Vandesompele J; Schramm A; van Noesel MM; Varesio L; Speleman F; Eggert A; Stallings RL; Caron HN; Versteeg R; Schulte JH
    Nat Genet; 2012 Nov; 44(11):1199-206. PubMed ID: 23042116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
    Helland Å; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DD
    PLoS One; 2011 Apr; 6(4):e18064. PubMed ID: 21533284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase.
    Chen D; Cox J; Annam J; Weingart M; Essien G; Rathi KS; Rokita JL; Khurana P; Cuya SM; Bosse KR; Pilgrim A; Li D; Shields C; Laur O; Maris JM; Schnepp RW
    Neoplasia; 2020 Apr; 22(6):231-241. PubMed ID: 32339949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
    Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
    Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
    Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
    Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
    Schnepp RW; Khurana P; Attiyeh EF; Raman P; Chodosh SE; Oldridge DA; Gagliardi ME; Conkrite KL; Asgharzadeh S; Seeger RC; Madison BB; Rustgi AK; Maris JM; Diskin SJ
    Cancer Cell; 2015 Nov; 28(5):599-609. PubMed ID: 26481147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
    Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
    J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine-mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling.
    Liu Y; Zhang J; Cao F; Dong X; Li J; Cao Y; Li Z; Guo Y; Yan J; Liu Y; Zhao Q
    JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37991019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.
    Kerosuo L; Neppala P; Hsin J; Mohlin S; Vieceli FM; Török Z; Laine A; Westermarck J; Bronner ME
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7351-E7360. PubMed ID: 30021854
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
    Planells-Ferrer L; Urresti J; Soriano A; Reix S; Murphy DM; Ferreres JC; Borràs F; Gallego S; Stallings RL; Moubarak RS; Segura MF; Comella JX
    Cell Death Dis; 2014 Sep; 5(9):e1401. PubMed ID: 25188511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.